Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Dr. Grothey on the Rationale to Evaluate Patritumab Deruxtecan in HER3+ CRC

February 16th 2021

Axel Grothey, MD, discusses the rationale to evaluate patritumab deruxtecan in HER3-positive colorectal cancer.

Dr. Raghav on the Utility of Chemotherapy-Free Intervals in CRC

February 15th 2021

Kanwal Raghav, MBBS, MD, discusses the utility of chemotherapy-free intervals in colorectal cancer.

ctDNA-Guided MRD Assessment Enters New Horizon in Colon Cancer

February 15th 2021

Finding a reliable biomarker for minimal residual disease assessment is needed and circulating tumor DNA has shown incredible promise in colon cancer.

Role of ctDNA Testing/Monitoring in Early-Stage CRC

February 15th 2021

A discussion on the evolving role of ctDNA (circulating tumor DNA) testing and monitoring in early-stage colorectal cancer (CRC).

Treatment Approach for Stage II/III Resectable CRC

February 15th 2021

Key opinion leaders discuss their approach for the treatment of patients with stage II/III resectable colorectal cancer (CRC), with special consideration of factors for choosing perioperative therapy and the management of low- vs high-risk patients.

Dr. Coveler on the Rationale to Evaluate NUC-3373 in Metastatic CRC

February 12th 2021

Andrew Coveler, MD, discusses the rationale to evaluate NUC-3373 in metastatic colorectal cancer.

Dr. Ciombor on Ongoing Research Efforts in Rectal Cancer

February 11th 2021

Kristen K. Ciombor, MD, MSCI, discusses ongoing research efforts being made in rectal cancer.

Grothey Spotlights Personalized Approaches Shaking Up CRC Care Continuum

February 10th 2021

Axel Grothey, MD, highlights recent advancements in CRC treatment, including innovative combinations and emerging agents that are generating excitement in the field.

Open Questions and Future Directions in mCRC

February 4th 2021

Experts in CRC discuss questions and management of mCRC.

Using Molecular Testing to Guide Treatment Selection in mCRC

February 4th 2021

John Marshall, MD, and Axel Grothey, MD, discuss how molecular testing results guide treatment decisions in patients with mCRC.

Drive-By Flu-FIT Program May Address CRC Screening Decline in Diverse Communities Amidst COVID-19 Crisis

February 3rd 2021

February 3, 2021 - The Drive-By Flu-Fecal Immunochemical Test program not only provides safe and socially distanced colorectal cancer screening opportunities during the coronavirus disease 2019 pandemic, but also may help to address screening declines in diverse communities.

ASCO Names Molecular Profiling in GI Cancers as Advance of the Year

February 2nd 2021

February 2, 2021 - ASCO has chosen molecular profiling driving progress in gastointestinal cancers as its Advance of the Year.

Dr. Ciombor on Sequencing Therapies in Locally Advanced Rectal Cancer

February 2nd 2021

Kristen K. Ciombor, MD, MSCI, discusses sequencing treatment options for patients with locally advanced rectal cancer.

TAS-102 in Third or Fourth Line for mCRC

February 1st 2021

Experts in mCRC review data on TAS-102 and discuss how best to sequence therapies in the third or fourth line.

Regorafenib in Third or Fourth Line for mCRC: Safety in the Re-DOS Trial

February 1st 2021

Axel Grothey, MD, and John Marshall, MD, discuss safety results from the ReDOS study of regorafenib in patients with mCRC.

Regorafenib in Third or Fourth Line for mCRC: Efficacy in the Re-DOS Trial

February 1st 2021

John Marshall, MD, reviews efficacy data from the ReDOS study of regorafenib in patients with mCRC.

Therapy After Progression in mCRC

February 1st 2021

Experts in metastatic colorectal cancer review therapeutic options after progression for patients with mCRC.

Maintenance or Chemo-Free Interval in mCRC

January 29th 2021

Experts in metastatic colorectal cancer discuss when and in which patients to use a chemotherapy-free treatment interval.

Optimizing First-Line Therapy in mCRC

January 29th 2021

Axel Grothey, MD, and John Marshall, MD, discuss strategies for optimizing first-line treatment in metastatic colorectal cancer and the role of adjuvant therapy.

Onvansertib Plus FOLFIRI/Bevacizumab Shows Preliminary Efficacy, Tolerability in Second-Line mCRC

January 27th 2021

January 27, 2021 - The combination of the polo-like kinase 1 inhibitor, onvansertib, with FOLFIRI and bevacizumab was found to have preliminary activity and favorable tolerability when used as a second-line treatment for patients with KRAS-mutated metastatic colorectal cancer.